The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1188
August 2, 2004
View Complete Issue         Table of Contents 2019 
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder
August 2, 2004 (Issue: 1188)
Trospium chloride (Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Trospium (Sanctura): Another Anticholinergic for Overactive Bladder
Article code: 1188c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.